Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NovaScan LLC

This article was originally published in Start Up

Executive Summary

The rates of reoperation after breast conservation therapy vary between 25 and 49%, due to the presence of tumor cells remaining in the surrounding tissue after the tumor is removed. NovaScan hopes to reduce the need for these reoperations. Its FastPath residual cancer probe is designed to identify normal, benign and malignant tissue types remaining inside the surgical cavity and in excised tissue in real time during surgery.

Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT037749

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel